HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

bis(maltolato)oxovanadium(IV)

a hypoglycemic agentt; structure given in first source

Also Known As:

BMOV IV; BMOV(IV)

Networked: 10 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - Pyrones: 35
      - bis(maltolato)oxovanadium(IV): 10
Inorganic Chemicals: 9
- Electrolytes: 16106
  - Ions: 7857
    - Anions: 3501
      - Vanadates: 512
        bis(maltolato)oxovanadium(IV): 10
- Vanadium Compounds: 87
  - Vanadates: 512
    - bis(maltolato)oxovanadium(IV): 10

Experts

1.	Cichon, Ann-Christin: 1 article (02/2015)
2.	Clark, Owen: 1 article (02/2015)
3.	Di Florio, Alessia: 1 article (02/2015)
4.	Jugov, Roman: 1 article (02/2015)
5.	Maeshima, Ruhina: 1 article (02/2015)
6.	Park, Inhye: 1 article (02/2015)
7.	Rustin, Sarah: 1 article (02/2015)
8.	Stoker, Andrew W: 1 article (02/2015)
9.	Bordbar, Abdol-Khalegh: 1 article (04/2009)
10.	Creagh, A Louise: 1 article (04/2009)

Related Diseases

1.	Hyperinsulinism (Hyperinsulinemia) 07/01/1994 - "Bis(maltolato)oxovanadium(IV) attenuates hyperinsulinemia and hypertension in spontaneously hypertensive rats." 01/01/1999 - "This is a preliminary study in which both acute and chronic oral administration of bis(maltolato)oxovanadium (IV) (BMOV) was examined in the Zucker diabetic fatty (ZDF) rat, an animal model that develops overt hyperglycemia in the presence of hyperinsulinemia followed by beta-cell depletion. " 09/01/1996 - "Chronic (6 weeks) oral administration of bis(maltolato)oxovanadium(IV) (0.06 mmol.kg-1.day-1, low dose study) was effective in reducing the hyperinsulinemia associated with the fatty Zucker rat model (termination insulin: lean, 82.8 +/- 21.6; fatty, 732 +/- 89.4; fatty treated, 336 +/- 126.6 pmol/L; p < 0.05). " 09/01/1996 - "These data indicate that chronic oral administration of bis(maltolato)oxovanadium(IV) in the drinking water was effective in reducing hyperinsulinemia, insulin resistance, glucose intolerance, and hypertension in the fatty Zucker rat."
2.	Insulin Resistance 01/01/2002 - "In this study we examined the effect of bis(maltolato)oxovanadium(IV) (BMOV) on PTP1B and its possible role in the amelioration of insulin resistance. " 09/01/1996 - "These data indicate that chronic oral administration of bis(maltolato)oxovanadium(IV) in the drinking water was effective in reducing hyperinsulinemia, insulin resistance, glucose intolerance, and hypertension in the fatty Zucker rat."
3.	Hypertension (High Blood Pressure) 07/01/1994 - "Bis(maltolato)oxovanadium(IV) attenuates hyperinsulinemia and hypertension in spontaneously hypertensive rats." 09/01/1996 - "These data indicate that chronic oral administration of bis(maltolato)oxovanadium(IV) in the drinking water was effective in reducing hyperinsulinemia, insulin resistance, glucose intolerance, and hypertension in the fatty Zucker rat."
4.	Glucose Intolerance 09/01/1996 - "These data indicate that chronic oral administration of bis(maltolato)oxovanadium(IV) in the drinking water was effective in reducing hyperinsulinemia, insulin resistance, glucose intolerance, and hypertension in the fatty Zucker rat."
5.	Alzheimer Disease (Alzheimer's Disease) 01/01/2023 - "Vanadium complexes, for instance, have shown promising results towards therapeutics of Alzheimer's Disease, most notably the bis(maltolato)oxovanadium (IV). "

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Drinking Water
3.	Vanadium
4.	growth hormone-releasing peptide-2 (KP 102)
5.	Streptozocin (Streptozotocin)
6.	Galactosyltransferases
7.	bis(ethylmaltolato)oxovanadium(IV)
8.	ethyl maltol

Related Therapies and Procedures

1.	Oral Administration
2.	Therapeutics